A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
Sponsor: Agenus Inc.
This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently ongoing. Agenus Inc. leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States , Aurora, United States , Austin, United States , Barcelona, Spain , Barnaul, Russia , Batumi, Georgia , Besançon, France , Boston, United States , Brasília, Brazil , Chelyabinsk, Russia and 42 more locations